ArticleAnnals of surgical oncology2018
Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database.
Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Breast conservation versus mastectomy for metaplastic breast cancer: A systematic review and meta-analysis.Asia-Pacific journal of clinical oncology · 2025Pooled it
- Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma.Scientific reports · 2020Trial
- A retrospective study of metaplastic breast cancer: Treatment and prognosis through chemotherapy followed by radiotherapy.Medicine · 2026Article
- Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.Discover oncology · 2026Article
- Metaplastic breast carcinoma versus triple-negative breast cancer: distinct metastatic patterns and inferior overall survival in a matched retrospective cohort study.Frontiers in oncology · 2026Article
- Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis.Annals of surgical oncology · 2025Article
- Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype.Annals of surgical oncology · 2025Article
- The Metaplastic Conundrum: A National Cancer Database Analysis of Metaplastic versus Triple-Negative Ductal Breast Cancer.Annals of surgical oncology · 2025Article
- Radiomics for Detecting Metaplastic Histology in Triple-Negative Breast Cancer: A Step Towards Personalized Therapy.Bioengineering (Basel, Switzerland) · 2025Article
- Survival outcomes after systemic treatment of high-grade triple-negative metaplastic breast cancer versus triple-negative breast cancer of no special type.Virchows Archiv : an international journal of pathology · 2025Article
- Demographic and clinical predictors of treatment outcomes in invasive lobular carcinoma breast cancer: insights from Cox regression analysis.Discover oncology · 2025Article
- Clinical Implication of Subcategorizing T2 Category in Metaplastic Breast Cancer.Journal of breast cancer · 2025Article
- Clinicopathological characteristics, treatments and oncological outcomes in metaplastic breast cancer: a Brazilian multicenter analysis.Frontiers in oncology · 2025Article
- Magnetic resonance imaging characteristics and survival outcomes of metaplastic breast carcinoma.PloS one · 2025Article
- Promising Response to Neoadjuvant Chemotherapy Plus Immunotherapy in Metaplastic Breast Carcinoma.Breast cancer (Dove Medical Press) · 2025Article
- Low-Grade Adenosquamous Carcinoma of the Breast: A Single-Center Retrospective Study and a Systematic Literature Review.Cancers · 2024Article
- Survival trends of patients with metaplastic breast carcinoma with different hormone receptor statuses: a SEER-based retrospective cohort study.BMC women's health · 2024Article
- Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Better Local Disease Control With Mastectomy in Metaplastic Breast Carcinoma: Findings of a Retrospective Cohort.Cureus · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMetaplastic breast cancer (MBC) is characterized by chemoresistance and hematogenous spread. We sought to identify factors associated with improved MBC outcomes and increased likelihood of MBC diagnosis.
methodsWomen ≥ 18 years of age with stage I-III MBC and non-MBC diagnosed between 2010 and 2014 were identified in the National Cancer Data Base. Kaplan-Meier and multivariate Cox proportional hazards models were used to estimate associations with overall survival (OS). Multivariate logistic regression identified factors associated with MBC diagnosis.
resultsOverall, 2451 MBC and 568,057 non-MBC patients were included; 70.3% of MBC vs. 11.3% of non-MBC patients were triple negative (p < 0.001). Five-year OS was reduced among MBC vs. non-MBC patients for the entire cohort (72.7 vs. 87.5%) and among triple-negative patients (71.1 vs. 77.8%; both p < 0.001). In MBC, triple-negative (vs. luminal) subtype was not associated with worse OS (hazard ratio [HR] 1.16, 95% confidence interval [CI] 0.88-1.54, p = 0.28). Compared with non-MBC patients, MBC patients were more likely to receive mastectomy (59.0 vs. 44.9%), chemotherapy (74.1 vs. 43.1%), and axillary lymph node dissection (ALND; 35.2 vs. 32.2%, all p ≤ 0.001). MBC patients more frequently had negative ALND (pN0) than non-MBC patients (20.0 vs. 10.6%, p < 0.001). Among MBC patients, chemotherapy (HR 0.69, 95% CI 0.53-0.89, p = 0.004) and radiotherapy (HR 0.52, 95% CI 0.39-0.69, p < 0.001) were associated with improved survival, while ALND was associated with decreased survival (HR 1.37, 95% CI 1.06-1.77, p = 0.02).
conclusionsMBC patients had worse survival than non-MBC patients, independent of receptor status, suggesting that MBC may confer an additional survival disadvantage. Multimodal therapy was associated with improved outcomes, but ALND was not and may be overutilized in MBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.